
Bhasker Dharavath
54 posts

















UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! nature.com/articles/s4169…


Pleased to share the dev' of DOME by @desaisanket12 and team! Thanks @NAR_Cancer_EIC & @ACTREC_TMC. This powerful comput'l framework identifies potential driver mutations, advanc'g personalized cancer therapy with emphas' on VUS ! @CRI_ACTREC @UnivofDelhi academic.oup.com/narcancer/arti…





The Tail & Tango of Cancer genome-- we developed a tool “DOME” to tame the tail of rare mutations; in another study, we describe the first chromosomal tango “Chr 11/5 fusion” in oral cancer genome. Thanks to @ACTREC_TMC,@CRI_ACTREC,@DBTIndia,@India_Alliance,@DAEIndia,@UnivofDelhi



UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! nature.com/articles/s4169…



UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! nature.com/articles/s4169…





UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! nature.com/articles/s4169…






